The all-cash deal will see Sanofi taking full control of the company, which focuses on treatments for multiple sclerosis and a range of autoimmune disorders, according to a statement Monday. Bloomberg reported last month that Sanofi was studying potential acquisitions of US biotechnology firms, including Principia.
from The Boston Globe https://ift.tt/3iOTKYH
The all-cash deal will see Sanofi taking full control of the company, which focuses on treatments for multiple sclerosis and a range of autoimmune disorders, according to a statement Monday. Bloomberg reported last month that Sanofi was studying potential acquisitions of US biotechnology firms, including Principia.
https://ift.tt/eA8V8J August 18, 2020 at 01:52AM
ليست هناك تعليقات:
إرسال تعليق